Home » Takeda Announces Mutual Termination of Amylin/Takeda Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
Takeda Announces Mutual Termination of Amylin/Takeda Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
Takeda Pharmaceutical Company announced that it has mutually terminated its worldwide agreement with Amylin Pharmaceuticals, originally signed in October 2009, to co-develop and commercialize compounds for obesity.
Yahoo! Finance
Yahoo! Finance
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May